Overview

PROPOSE Quality - PReOtact in Postmenopausal OStEoporosis - Quality of Life Study (FP-004-DE)

Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
0
Participant gender:
Female
Summary
The objectives of the study are - to describe the quality of life at the beginning of the Preotact® treatment and at the end of the observational period (Qualeffo-41 questionnaire) - pain assessment at the beginning of the Preotact® treatment and at the end of the observational period (VAS score) - to describe bone mineral density at the beginning of the Preotact® treatment and at the end of the observational period (T-Score) - to describe incidence of bone fractures caused by osteoporosis as well as of other pathological findings of the skeleton after the beginning of the Preotact® treatment - to describe serum level of calcium and the bone resorption marker desoxypyridinoline (DPD) and N- respectively C-terminal crosslink-telopeptide (CTX and NTX) at the beginning of the Preotact® treatment and at the end of the observational period (only in subgroup of patients, where the physician sees a need to measure these parameters) - to document all adverse drug reactions after the beginning of the Preotact® treatment - the analysis of subgroups with different risk for bone fractures caused by osteoporosis at the beginning of the Preotact® treatment - to assess the manageability and functioning of the Pen system for injection of Preotact® (self administered questionnaire)
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Nycomed
Treatments:
Hormones
Parathyroid Hormone
Criteria
Inclusion Criteria:

- Inclusion requires that Preotact® is prescribed in accordance with the SPC and that
the stated contraindications are strictly considered.

- Caution should be taken by the treating Physician concerning any precautions, warnings
and potential drug interactions stated in the SPC.

- No further inclusion or exclusion parameters are defined. The decision for the
individual application of Preotact® will be strictly made by the physicians.